LANOXICAPS
LOE ApproachingNDAORALCAPSULE
Approved
Jul 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANOXICAPS is an oral capsule formulation of a small-molecule cardiac glycoside approved in 1982. The generic composition and mechanism of action are not specified in available data, but the product class suggests cardiovascular utility. Patient population and specific indications require clarification from regulatory sources.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect streamlined commercial team and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity; LANOXICAPS roles are typically stable, legacy positions with limited career mobility. Working on this product offers execution experience in a mature market but fewer learning opportunities than growth-stage assets.
Brand ManagerField Sales Representative
Worked on LANOXICAPS at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.